Abstract

Annals of NeurologyVolume 91, Issue 5 p. 732-733 Letters/Replies A Letter Concerning “Aducanumab: What about the Patient?” Sam Gandy MD, PhD, Corresponding Author Sam Gandy MD, PhD [email protected] orcid.org/0000-0001-6455-4721 Departments of Neurology and Psychiatry and the Mount Sinai Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY Research and Development Service, James J Peters VA Medical Center, Bronx, NY Address correspondence to Sam Gandy, Departments of Neurology and Psychiatry and the Mount Sinai Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029-5674. E-mail: [email protected]Search for more papers by this author Sam Gandy MD, PhD, Corresponding Author Sam Gandy MD, PhD [email protected] orcid.org/0000-0001-6455-4721 Departments of Neurology and Psychiatry and the Mount Sinai Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY Research and Development Service, James J Peters VA Medical Center, Bronx, NY Address correspondence to Sam Gandy, Departments of Neurology and Psychiatry and the Mount Sinai Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029-5674. E-mail: [email protected]Search for more papers by this author First published: 17 February 2022 https://doi.org/10.1002/ana.26333Citations: 1Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article.Citing Literature Volume91, Issue5May 2022Pages 732-733 RelatedInformation

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call